jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Apogee Therapeutics, LLC

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Apogee Therapeutics, LLC
Via GlobeNewswire
Tickers APGE
Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News